Fortunately, the PD-L1 inhibition as a single-molecule target for therapy has been proved to ameliorate the progression-free survival (PFS) in TNBC patients, and CDK4/6 inhibitors substantially improve PFS of BC patients with endocrine resistance in recent years, although not for all BC patients (Schmid et al., 2018; Turner et al., 2018; Harbeck et al., 2019). The gene discussed is CDK4; the disease is breast cancer.